Dipartimento di Medicina Molecolare e dello Sviluppo, Università di Siena - Divisione di Psichiatria, Sistema Sanitario Nazionale della Lombardia, Mantova.
Sod di Psichiatria, Azienda Ospedaliero-Universitaria Careggi, Firenze.
Riv Psichiatr. 2019 Jul-Aug;54(4):137-149. doi: 10.1708/3202.31796.
To provide a review of the clinically relevant evidence pertaining to the use of trazodone in major depressive disorder.
Medline and Cochrane Library searches were searched using the keywords 'trazodone' AND 'depression', to identify the most relevant literature pertinent to the pharmacological properties of trazodone and its use in clinical practice. Articles that were selected included basic pharmacology papers, clinical trials, clinical practice guidelines, and reviews. Related references were cross checked. European and United States prescribing information was reviewed as well. An effort was made to give weight to the information that was most relevant for daily clinical practice.
Trazodone is an antidepressant with a mechanism of action that remains innovative and with a favorable profile for the treatment of depression. The appropriate antidepressant doses are usually 150-300 mg/day and are often higher than the doses that are used when trazodone is prescribed to augment the antidepressant effect of another medication, for instance when trazodone is prescribed to address insomnia in a patient treated with an SSRI. Trazodone is usually well tolerated and has a low risk of anticholinergic side effects, weight gain and sexual side effects.
Trazodone is an established medication that is efficacious for the treatment of a broad array of depressive symptoms, including symptoms that are less likely to respond to other antidepressants (e.g. SSRI), such as insomnia. As an antidepressant, trazodone has proven as efficacious as the tricyclic and second-generation antidepressants and is tolerated relatively well. Trazodone may be helpful for patients with major depression and comorbid insomnia, anxiety or psychomotor agitation.
Trazodone is efficacious antidepressants with a relatively low risks of side effects such as weight gain, sexual or anticholinergic effects (such as constipation, urinary retention, dry mouth). In addition to being able to control a wide range of depressive symptoms, trazodone may improve sleep and be particularly helpful for patients whose symptoms of depression include insomnia.
综述曲唑酮治疗重度抑郁症的临床相关证据。
使用关键词“曲唑酮”和“抑郁”在 Medline 和 Cochrane Library 中进行检索，以确定与曲唑酮药理学特性及其在临床实践中的应用最相关的文献。选择的文章包括基础药理学论文、临床试验、临床实践指南和综述。同时交叉核对了相关参考文献。还查阅了欧洲和美国的处方信息。努力提供与日常临床实践最相关的信息。
曲唑酮是一种具有创新作用机制的抗抑郁药，其治疗抑郁症的效果良好。适当的抗抑郁剂量通常为 150-300mg/天，通常高于曲唑酮用于增强另一种药物抗抑郁作用的剂量，例如曲唑酮用于解决接受 SSRI 治疗的患者的失眠问题。曲唑酮通常耐受性良好，抗胆碱能副作用、体重增加和性功能障碍的风险较低。
曲唑酮是一种已被证实的药物，可有效治疗广泛的抑郁症状，包括对其他抗抑郁药（如 SSRI）反应较差的症状，如失眠。作为一种抗抑郁药，曲唑酮已被证明与三环类和第二代抗抑郁药同样有效，且耐受性相对较好。曲唑酮可能对伴有失眠、焦虑或精神运动性激越的重度抑郁症患者有帮助。
曲唑酮是一种有效的抗抑郁药，副作用风险相对较低，如体重增加、性功能或抗胆碱能效应（如便秘、尿潴留、口干）。除了能够控制广泛的抑郁症状外，曲唑酮还可以改善睡眠，对伴有失眠症状的患者尤其有帮助。
